Anika Therapeutics (ANIK) Misses Q4 EPS by 10c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.81 -1.05%
EPS Growth %: -25.0%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -25.0%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $39.62 million versus the consensus estimate of $37.71 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- Arrive AI and DXC Technology partner to bring delivery tech to factories
- Corpay agrees to $100M FTC settlement over marketing practices
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
